|Articles|March 1, 2012
- BioPharm International-03-01-2012
- Volume 25
- Issue 3
BioPharm International, March 2012 Issue (PDF)
Scale-Up of Human Stem Cells
Advertisement
Articles in this issue
over 13 years ago
Biosimilar Developers Face a Reference-Product Dilemmaover 13 years ago
Communications Advances Present Challenges to Manufacturersover 13 years ago
The Drive for Best Practice in Biopharmaceutical Manufacturingover 13 years ago
CMOs Face a Kodak Momentover 13 years ago
FDA Guides the Way to Biosimilars in the USover 13 years ago
Assessing Filling Technologies For Contamination Riskover 13 years ago
Putting Risk-Based Decision-Making Where It BelongsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
